Ascoli Bartoli, Tommaso
Lepore, Luciana
D’Abramo, Alessandra
Adamo, Giovanna
Corpolongo, Angela
Scorzolini, Laura
Giancola, Maria Letizia
Bevilacqua, Nazario
Palazzolo, Claudia
Mariano, Andrea
Ippolito, Giuseppe
Buffet, Pierre
Nicastri, Emanuele
Article History
Received: 28 August 2020
Accepted: 16 April 2021
First Online: 29 April 2021
Declarations
:
: The present research is based on data reported in previously published works. The patient enrolled at INMI “L. Spallanzani” IRCCS, whose data have never been analysed and published before, has signed an informed consent to participate to observational research protocols.
: The present research is based on data reported in previously published works. The patient enrolled at INMI “L. Spallanzani” IRCCS, whose data have never been analysed and published before, has signed an informed consent for data publication.
: The research team of Pierre Buffet received support from Guilin Laboratories in 2017–2020 for the surveillance of artesunate efficacy and toxicity in France. The author provided expertise for FastTrack Drugs & Biologics LLC and Sigma-Tau Pharmaceuticals from 2013 to 2016, and provided expertise to Sanofi Aventis Research & Development from 2013 to 2015.All other authors report no potential conflicts.